Pretherapeutic screening for Dihydropyrimidine deshydrogenase deficiency in measuring uracilemia in dialysis patients leads to a high rate of falsely positive results-Reference-Cited by-同舟云学术

Pretherapeutic screening for Dihydropyrimidine deshydrogenase deficiency in measuring uracilemia in dialysis patients leads to a high rate of falsely positive results

Published:2021-09-13 Issue:6 Volume:88 Page:1049-1053
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Gaible Clotilde,Narjoz Céline,Loriot Marie-Anne,Roueff Stéphane,Pallet Nicolas^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00280-021-04354-7.pdf

Reference17 articles.

1. Butler AM, Olshan AF, Kshirsagar AV et al (2015) Cancer incidence among US medicare ESRD patients receiving hemodialysis, 1996–2009. Am J Kidney Dis 65(5):763–772. https://doi.org/10.1053/j.ajkd.2014.12.013

2. Janus N, Launay-Vacher V, Thyss A et al (2013) Management of anticancer treatment in patients under chronic dialysis: results of the multicentric CANDY (CANcer and DialYsis) study. Ann Oncol 24(2):501–507. https://doi.org/10.1093/annonc/mds344

3. Andre T, Colin P, Louvet C et al (2003) Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 21(15):2896–2903. https://doi.org/10.1200/JCO.2003.10.065

4. van Kuilenburg ABP (2004) Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40(7):939–950. https://doi.org/10.1016/j.ejca.2003.12.004

5. Meulendijks D, Henricks LM, Sonke GS et al (2015) Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol 16(16):1639–1650. https://doi.org/10.1016/S1470-2045(15)00286-7

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of renal impairment on dihydropyrimidine dehydrogenase (DPD) phenotyping;ESMO Open;2023-06

2. Discrepancies between dihydropyrimidine dehydrogenase phenotyping and genotyping: What are the explanatory factors?;British Journal of Clinical Pharmacology;2023-03-30

3. Screening for dihydropyrimidine dehydrogenase deficiency by measuring uracilemia in chronic kidney disease patients is associated with a high rate of false positives;Clinica Chimica Acta;2023-03

4. Assay performance and stability of uracil and dihydrouracil in clinical practice;Cancer Chemotherapy and Pharmacology;2023-03

5. Phenotype/Genotype Discrepancy of DPD Deficiency Screening in a Patient With Severe Capecitabine Toxicity: A Case Report;JCO Precision Oncology;2023-03